Business Valuation Zone

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

topic pharma-stocks

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

JANUARY 23, 2024

Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022. Dry powder’ With record levels of cash on balance sheet, big pharma had plenty of “dry powder” available and was not afraid to get off the sidelines. billion, Mirati for $5.8

Marketability

Marketability Equity Private Equity Firm Finance

Gibson Dunn Offers 2022 Mid-Year Securities Litigation Update

Reynolds Holding

OCTOBER 5, 2022

Aspects of the decision in Goldstein suggest this is a topic that the court may be interested in exploring more in the future. On June 29, 2022, Judge Koeltl granted final certification of the settlement class, consisting of all persons or entities who acquired common stock of SCWorx between April 13, 2020 and April 17, 2020.

Start-ups

Start-ups Marketability Equity Compliance

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Gibson Dunn Offers 2022 Mid-Year Securities Litigation Update

Stay Connected